Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Shares Issued (2020 - 2024)

Historic Shares Issued for TScan Therapeutics (TCRX) over the last 5 years, with Q4 2024 value amounting to $30.0 million.

  • TScan Therapeutics' Shares Issued changed N/A to $30.0 million in Q4 2024 from the same period last year, while for Sep 2025 it was $158.0 million, marking a year-over-year increase of 2318.59%. This contributed to the annual value of $158.3 million for FY2024, which is 7144.11% up from last year.
  • TScan Therapeutics' Shares Issued amounted to $30.0 million in Q4 2024.
  • TScan Therapeutics' 5-year Shares Issued high stood at $128.0 million for Q2 2024, and its period low was -$76000.0 during Q3 2023.
  • Moreover, its 5-year median value for Shares Issued was $69000.0 (2022), whereas its average is $19.1 million.
  • Its Shares Issued has fluctuated over the past 5 years, first skyrocketed by 894760000.0% in 2021, then tumbled by 162000.0% in 2023.
  • TScan Therapeutics' Shares Issued (Quarter) stood at $40000.0 in 2020, then skyrocketed by 223592.5% to $89.5 million in 2021, then tumbled by 99.92% to $69000.0 in 2022, then crashed by 210.14% to -$76000.0 in 2023, then surged by 39572.37% to $30.0 million in 2024.
  • Its Shares Issued was $30.0 million in Q4 2024, compared to $128.0 million in Q2 2024 and $258000.0 in Q1 2024.